RxDoctor Payments Data

Stephen Cullen, MD

Family Medicine · Medina, OHNPI 1740250802

Payments from drug & device makers

$343in general payments, 2019–2025

Across 22 payments — averaging $15.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$120
  • GSK$44
  • Abbott$35
  • Astellas Pharma US Inc$28
  • Sanofi-aventis U.S. LLC$22
  • Antares Pharma, Inc.$19
  • plus $74 from 5 others

What the payments were for

  • Food & beverage$343100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer8$120
GSK3$44
Abbott2$35
Astellas Pharma US Inc2$28
Sanofi-aventis U.S. LLC1$22
Antares Pharma, Inc.1$19
Mayne Pharma Commercial LLC1$18
Amgen1$16
AbbVie1$15
Nalpropion Pharmaceuticals LLC1$13
Novo Nordisk1$12

How this compares

$343 in reported general payments places this provider in the 45th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$88,919
Medicare patients
427
Services billed
1,804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban115$125,778
FarxigaDapagliflozin Propanediol90$82,185
OzempicSemaglutide61$73,244
JardianceEmpagliflozin59$72,312
TrulicityDulaglutide65$63,209
JanuviaSitagliptin Phosphate38$46,014
TradjentaLinagliptin35$31,786
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$26,073
XareltoRivaroxaban21$25,520
Soliqua 100-33Insulin Glargine/Lixisenatide15$17,366
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$13,217
MounjaroTirzepatide12$12,469
Atorvastatin Calcium1,295$11,006
Fluticasone-SalmeterolFluticasone Propion/Salmeterol53$10,732
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog25$10,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$120$125,778115 claims
Novo NordiskOzempic$12$73,24461 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$44$48,28466 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$22$17,36615 claims
AbbVieSynthroid$15$4,460149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Medina

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →